Sign In
Buy ENTX
$2.99
+0.0400 (+1.36%)
At Close: Jul 31, 2026
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
04:30pm, Friday, 31'st Jul 2026
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief E
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
03:00pm, Wednesday, 29'th Jul 2026
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd.
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
12:03pm, Wednesday, 29'th Jul 2026
Entera Bio Ltd. (NASDAQ:ENTX) shares traded higher Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million.
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
08:30am, Monday, 27'th Jul 2026
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
11:40am, Tuesday, 21'st Jul 2026
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
08:50am, Tuesday, 23'rd Jun 2026
Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, cre
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
08:50am, Tuesday, 23'rd Jun 2026
Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, cre
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts acr
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
04:05pm, Friday, 08'th May 2026
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitte
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 29'th Apr 2026
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
01:21pm, Monday, 20'th Apr 2026
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
11:59am, Monday, 20'th Apr 2026
In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis
